SCHEMBL4068400

SCHEMBL4068400

CN(Cc1ncc[nH]1)Cc1nccn1Cc1ccc(CN2CCC3(CCNCC3)C2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.49
KDM1A O60341 1/20 0.45
MAOB P27338 1/20 0.45
RCOR1 Q9UKL0 1/20 0.45
CYP2D6 P10635 6/20 0.43
CYP3A4 P08684 4/20 0.43
ALDH1A1 P00352 3/20 0.43
CYP2C19 P33261 2/20 0.43
HPGD P15428 1/20 0.41
TSHR P16473 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2C9 P11712 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HIF1A Q16665 1/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.34
TAAR1 Q96RJ0 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073933 0.89 CXCR4 (0.60) CXCR4KDM1AMAOBRCOR1CYP2D6
SCHEMBL4067026 0.86 CXCR4 (0.42) CXCR4KDM1AMAOBRCOR1CYP2D6
SCHEMBL4070832 0.79 CXCR4 (0.39) CXCR4KDM1AMAOBRCOR1ALDH1A1
SCHEMBL4075810 0.78 CXCR4 (0.59) CXCR4CYP2D6CYP3A4ALDH1A1CYP2C19
SCHEMBL4070793 0.77 CXCR4 (0.54) CXCR4CYP2D6CYP3A4ALDH1A1CYP2C19
SCHEMBL4067735 0.76 CXCR4 (0.52) CXCR4CYP2D6CYP3A4ALDH1A1TSHR
SCHEMBL4069468 0.76 CXCR4 (0.52) CXCR4CYP2D6CYP3A4ALDH1A1TSHR
SCHEMBL4070682 0.75 CXCR4 (0.46) CXCR4CYP2D6CYP3A4ALDH1A1CYP2C19
SCHEMBL4071927 0.74 CXCR4 (0.42) CXCR4CYP2D6CYP3A4ALDH1A1CYP2C19
SCHEMBL4521932 0.73 CXCR4 (0.39) CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2055705-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF Ono Pharmaceutical CO., LTD. (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF CXCR4, CXCL12, CXCR1 CXCR4 1/4885KDM1A 4700/4885MAOB 3403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.